Health insurance catalog adjustment, can not be ignored two key!

Guide: After the surge in blood pressure, the exciting health care catalog adjustment has begun! According to the National Health Insurance Administration's annual health insurance catalog adjustment reporting program, August 21, 2020 at 9:00, until August 30, the Sunday 17:00 for pharmaceutical companies online filing time.
the declaration of your company's varieties completed? In the past into the health insurance catalog is a good business to break the head, many varieties of agents, the amount of a major advantage on the variety of health insurance.
now, the prospect of entering the health-care market may not be as great as it used to be.
the latest round of medicare catalog adjustments has two new features compared to previous catalog adjustments: one is to bring payment standards into the catalog.
In the past, the adjustment of the medical insurance catalogue was reviewed by experts in the organization, and the list of recommendations for the four aspects of medicines, such as new transfers, direct transfers, transfers, adjustments and limited payment ranges, was basically completed, but this year the principle of negotiation and bidding was increased.
, after the list of recommendations has been established, the Health Insurance Board will organize measurement experts to conduct assessments and make recommendations through fund measurements, drug economics, etc.
the evaluation of the experts and enterprises to negotiate or bid, determine the national unified standard of payment for health insurance, and simultaneously clear management policies.
means that this year's adjustment into the new health insurance catalog of varieties, are with price access, prices can not be discussed there is no way into the catalog.
In addition, it should be noted that, in addition to the price, the document also said that synchronization to clear management policy, only meet the reimbursement conditions can be reimbursed, for example, before some of the types of medical insurance directory have been added reimbursement restrictions, such as only the use of more than two hospitals can be reimbursed, only the use of specific diseases can be reimbursed, which implies that some medical community recognized the use of hyper-adaptation or over-catalog use, it is easy to face medical insurance denial.
hospitals may be more stringent in their management of drugs.
In the clear price, we can see that the obvious trend is that opening the door to the health care catalog is only the first step in the long march, as before, entering the catalog means that the era of good markets is gone.
, access to innovative drugs sets a timetable.
in its 2019 Medicare Directory Adjustment Program, it is clear that the time range for the approval of drugs that can be included in the new health insurance catalog is December 31, 2018 (inclusive) drugs previously registered with the State Drug Administration.
this year, the health-care catalog is very different in time. the
adjustment plan clearly states that the time range for approval of products that can be declared into the medical insurance catalogue is as follows: to include the list of new drugs that are urgently needed abroad in clinical practice, to encourage generic drugs, or to encourage research and development to declare the list of children's drugs, and to approve the list of drugs listed by the State Drug Administration before August 17, 2020 (inclusive, the same below).
between January 1, 2015 and August 17, 2020, the new generic drug was approved for sale by the State Drug Administration.
January 1, 2015 to August 17, 2020, according to the results of clinical trials to the State Drug Administration supplementary application and approval, adaptation, functional treatment and other significant changes in the drug.
From the above approval time, one is able to apply for supplementary access to the health insurance catalog of varieties are approved after 2015 products, no longer as broad as before, the former health insurance access is as long as there is no access to health insurance innovative drugs can be applied for, but now there is time to close, must be nearly 5 years or 6 years approved varieties can apply to enter the health insurance catalog.
second, the deadline has been delayed.
's previous request for comments was approved by December 31, 2019, and the official document was relaxed to August 17 this year.
does that mean? If future changes to the health insurance catalog are extended to this year's rules, then, in fact, innovative drugs only five years and eight health insurance access window period.
To put it another way, the door to the health-care catalog was always open, but now the rules are that if you haven't been in the catalog for more than five years or a while, you're probably out of the way.
rule changes have a huge impact on innovative medicines.
well known, the successful launch of innovative drugs is always only the first step.
In order to transform innovative medicines into medical services, market returns must be passed on to doctors the advances in medical knowledge and disease diagnosis that are attached to them."
, at the beginning of the market, its price must have enough room for academic promotion, to build academic promotion platform, team, landing its promotion strategy.
taken into account, it may not be cost-effective for innovative drugs to apply for health insurance as soon as they go on the market.
On the one hand, from the beginning to build a promotion team invested a lot, on the other hand, after the construction of the team, must continue to have new product input, do not do a hammer sale, in order to continue to reduce costs, and this requires pharmaceutical companies must continue to innovate or continue to introduce innovative drugs.
, this prescribed time method for domestic pharmaceutical companies a lot of pressure.
Some might say that the price of getting into health insurance is actually about the same as the price of a charity gift, but what you need to know is that the price has been slashed, and if the marketing is not good, even if you withdraw from health insurance after that, the price has not gone back.
so, for many home-grown innovative drugs, if the health-care catalog is adjusted to this time limit thereafter, it means that five or six years from now, there will be no access to the health-care catalog.
this time rhythm, leaving only three or four years of marketing space for innovative drugs.
this puts forward higher demands on the time, efficiency and rhythm of the domestic market for innovative drugs.
this time rhythm is good news for multinational pharmaceutical companies.
on the one hand, with the volume of procurement of the original research replacement, its expired original research drug market pressure is growing, on the other hand, the review and approval system reform, so that a large number of foreign enterprises innovative drugs into China.
Multinational pharmaceutical companies in the hierarchical hospital marketing play flying, there are talent, there are teams, because there are teams and talent pool, at this time, new drugs only increase marginal costs, no need for a new large-scale investment.
that they can completely let those product lines represent the transfer of posts and so on.
, of course, the price is against the international price.
because of the team and talent pool, at this time, new drugs only increase marginal costs, there is no need for a new large investment.
For enterprises, under the overall pressure of health care control fees, whether it is with volume procurement or the adjustment of the health insurance catalog, the product life cycle changes greatly, how to quickly and more market share in as soon as possible is more important than ever.
more urgent than ever to improve the efficiency and effectiveness of marketing as soon as possible while reducing the cost of promotion.
.